Skip to main content

Table 1 Select baseline characteristics in women according to APOE genotype status

From: Hormone replacement therapy is associated with improved cognition and larger brain volumes in at-risk APOE4 women: results from the European Prevention of Alzheimer’s Disease (EPAD) cohort

 

Non-E4 (n=675)

E4 (n=399)

Total (n=1074)

PAPOE

Age (mean, SD)

65.2 (7.3)

65.1 (7.3)

65.1 (7.3)

NS

Years of education (mean, SD)

14.4 (3.8)

13.8 (3.6)

14.1 (3.7)

0.014

Marital status (n, %)

   

NS

 Married/cohabiting

443 (65.6)

280 (70.0)

723 (67.5)

 

 Divorced

108 (16.0)

48 (12.0)

156 (14.3)

 

 Single

64 (9.5)

31 (7.8)

95 (8.5)

 

 Widowed

59 (8.7)

40 (10.0)

99 (9.6)

 

Handedness (right/left)

614/46

371/17

985/63

NS

CDR (n, %)

   

NS

 0.0

477 (71.6)

265 (68.5)

742 (70.2)

 

 0.5

189 (28.4)

122 (31.5)

337 (29.8)

 

HRT use

   

NS

 Yes/no

52/623

31/368

83/991

 

 Current/past users

46/6

30/1

76/7

 

 Duration in years (mean, SD)

7.2 (6.26)

8.0 (7.17)

7.5 (6.58)

 

 Age at HRT initiation (years)

56.2 (8.36)

56.5 (7.01)

56.4 (7.83)

 

Current CV medication (n, %)

196 (29.0)

130 (32.5)

326 (30.4)

NS

  1. NS non-significant, CDR Clinical Dementia Rating, CV cardiovascular